The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†
Open accessAbstract
UNLABELLED: Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomized controlled trials (RCTs) of new therapeutic approaches; however, survival of patients in the absence of treatment is highly variable, and prognostic factors influencing outcomes are incompletely defined. The aims of this meta-analysis were to estimate the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of palliative treatments, and to identify prognostic factors. RCTs evaluating therapies for HCC with placebo or no-treatment arms were identified on MEDLINE through April 2009. Data were combined in a random effect model. Primary outcomes were 1-year and 2-year survival. Thirty studies met the inclusion criteria. The pooled estimates of the survival rates were 17.5% at 1 year (95% confidence interval [95%CI], 11%-27%; range, 0%-75%) and 7.3% at 2 years (95%CI, 3.9%-13%; range, 0%-50%). Heterogeneity among studies was highly significant (P < 0.0001) both for 1-year and 2-year survival, and persisted when RCTs were stratified according to all patient and study features. Through meta-regression, impaired performance status, Child-Pugh B-C class, and presence of portal vein thrombosis were all independently associated with shorter survival. Ascites was strongly linked to a worse outcome in intermediate/advanced Barcelona Clinic Liver Cancer stages. CONCLUSION: This meta-analysis confirms the heterogeneity of behavior of untreated HCC and provides a sound basis for stratifying patients with HCC according to expected survival in future trials of new anti-cancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Self-citationLlovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationLlovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citationLo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citation(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Self-citationPelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Bañares, R., Albillos, A., Rincón, D., Alonso, S., González, M., Ruiz-del-Arbol, L., Salcedo, M., & Molinero, L.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.31354 · Cited by 364
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Tandon, P., & Garcia‐Tsao, G. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01957.x · Cited by 354
Major achievements in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60381-0 · Cited by 283
Self-citationTreatment of hepatocellular carcinoma with octreotide: a randomised controlled study
Kouroumalis, E., Skordilis, P., Thermos, K., Vasilaki, A., Moschandrea, J., & Manousos, O. N. (1998) · Gut · doi:10.1136/gut.42.3.442 · Cited by 280
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Self-citationRecombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J. (1993) · Hepatology · doi:10.1002/hep.1840170307 · Cited by 221
Chow, P. K. H., Tai, B.-C., Tan, C.-K., Machin, D., Win, K. M., Johnson, P. J., & Soo, K.-C. (2002) · Hepatology · doi:10.1053/jhep.2002.36824 · Cited by 209
Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial
(1998) · The Lancet · doi:10.1016/s0140-6736(98)01259-8 · Cited by 202
Effect of Telmisartan on Renal Outcomes: A Randomized Trial
Mann, J. F. E., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., Wang, X., Probstfield, J. L., Avezum, A., Cardona-Munoz, E., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-1-200907070-00122 · Cited by 196
Castells, A., Bruix, J., Brú, C., Ayuso, C., Roca, M., Boix, L., Vilana, R., & Rodés, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90402-6 · Cited by 187
Self-citationYuen, M.-F., Poon, R. T.-P., Lai, C.-L., Fan, S.-T., Lo, C.-M., Wong, K.-W., Wong, W. M., & Wong, B. C.-Y. (2002) · Hepatology · doi:10.1053/jhep.2002.35071 · Cited by 184
Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma
Barbare, J., Bouché, O., Bonnetain, F., Raoul, J., Rougier, P. R., Abergel, A., Boige, V., Denis, B., Blanchi, A., Pariente, A. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.470 · Cited by 134
Grimaldi, C. H., Bleiberg, H., Gay, F., Messner, M., Rougier, P. R., Kok, T. C., Cirera, L., Cervantes, A. M. R., Grève, J. D., Paillot, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.411 · Cited by 132
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
Martínez-Cerezo, F. J., Tomás, A., Donoso, L., Enríquez, J., Guarner, C., Balanzó, J., Martínez‐Noguera, A., & Vilardell, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80138-2 · Cited by 126
Becker, G., Allgaier, H., Olschewski, M., Zähringer, A., & Blum, H. E. (2006) · Hepatology · doi:10.1002/hep.21468 · Cited by 115
Villa, E., Ferretti, I., Grottola, A., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1534 · Cited by 96
Liu, C.-L., Fan, S.-T., Ng, I. O., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01688.x · Cited by 93
Barbare, J., Bouché, O., Bonnetain, F., Dahan, L., Lombard‐Bohas, C., Faroux, R., Raoul, J., Cattan, S., Lemoine, A., Blanc, J., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.018 · Cited by 64
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Intermediate HCC (BCLC stage B): Untreated patients at an intermediate stage – BCLC B class (multinodular asymptomatic tumors without an invasive pattern) present a median survival of 16 months [139,164], or 49% at 2 year [133].”
BackgroundInfluentialForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationEvidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Metadata
- Authors
- Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C.
- Venue
- Hepatology
- Published
- 2010-04
- Volume
- 51
- Issue
- 4
- Pages
- 1274-1283
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2051193106
- Cited by
- 473
- References
- 35
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.